<DOC>
	<DOCNO>NCT00644384</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention use certain drug keep cancer forming . The use acitretin may stop cancer grow patient high risk basal cell carcinoma squamous cell carcinoma skin . PURPOSE : This randomized trial study well acitretin work prevent skin cancer patient high risk skin cancer .</brief_summary>
	<brief_title>Acitretin Preventing Skin Cancer Patients High Risk Skin Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine chemopreventive efficacy acitretin , synthetic retinoid , patient high risk basal cell carcinoma ( BCC ) squamous cell carcinoma ( SCC ) skin . - Evaluate human papillomavirus ( HPV ) possible etiologic cofactor development cutaneous epidermal dysplasia/carcinoma skin tissue patient high risk BCC SCC skin . - Determine effect acitretin series potential surrogate endpoint biomarkers ( SEBs ) , include specific retinoid receptor ; Fos/Jun family proto-oncogene product ; Fos/Jun family transcription factor complex know activate protein 1 ( AP-1 ) ; HPV DNA normal ( sun-protected ) , sun-exposed dysplastic carcinoma ( SCC/BCC ) skin specimen . - Correlate standard clinical histopathological dermatologic evaluation modulation SEBs . OUTLINE : This multicenter study . Patients stratify accord age ( 18-49 year v 50-59 year v 60-69 year vs ≥ 70 year ) , number skin cancer within past 5 year ( 2-5 v 6-10 vs 11-20 v 21-30 v &gt; 30 ) , recent skin cancer occurrence ( &lt; 12 month ago vs ≥ 12 month ago ) , patient-reported sunburn susceptibility Fitzpatrick skin type ( 1 vs 2 v 3 v 4 v 5 v 6 ) , assessment visible skin damage ( minimal v moderate v extensive ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral acitretin 5 day week 2 year absence unacceptable toxicity . - Arm II : Patients receive oral placebo 5 day week 2 year absence unacceptable toxicity . Tissue sample normal skin , excise squamous cell basal cell carcinoma , excise actinic keratoses obtain baseline periodically study . Tissue sample analyze surrogate endpoint biomarkers , include RARγ , RXRα , Fos/Jun family proto-oncogene product , AP-1 DNA binding activity , presence , identification , quantification HPV DNA . mRNA protein expression level RARγ , RXRα , Fos/Jun family member analyze northern blot and/or quantitative polymerase chain reaction ( PCR ) method . HPV analyze PCR . After completion study treatment , patient follow every 6 month 5 year .</detailed_description>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Acitretin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : At high risk basal cell carcinoma ( BCC ) squamous cell carcinoma ( SCC ) skin , define prior history ≥ 3 nonmelanoma skin lesion All visible BCC SCC must resect prior study entry PATIENT CHARACTERISTICS : Life expectancy &gt; 5 year Alkaline phosphatase ≤ 2.5 time upper limit normal ( ULN ) SGOT ≤ 2 time ULN Creatinine ≤ 1.5 time ULN Cholesterol &lt; 250 mg/dL Triglycerides &lt; 2.5 time ULN Not pregnant No history significant , uncontrolled hyperlipidemia No history oral retinoid intolerance No history significant medical condition , opinion physician , would contraindicate retinoid use PRIOR CONCURRENT THERAPY : More 1 year since prior retinoid therapy At least 4 week since prior concurrent use oral vitamin A supplement , topical retinoids , potentially irritate skin preparation Concurrent multivitamin supplement allow No prior organ transplantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>basal cell carcinoma skin</keyword>
	<keyword>squamous cell carcinoma skin</keyword>
</DOC>